吡柔比星与其他灌注化疗药物预防膀胱肿瘤复发疗效比较的Meta分析

目的 比较吡柔比星与其他灌注化疗药物预防膀胱肿瘤复发的疗效. 方法检索Medline、EMBase、CBMDisc等文摘数据库以及PubMed、ScienceDirect、Lww、Springer、中国期刊全文数据库、中文科技期刊数据库等全文数据库,收集并按照纳入和排除标准筛选已发表的关于吡柔比星与其他膀胱灌注化疗药物预防膀胱肿瘤术后复发疗效比较的对照研究,提取纳入研究中关于复发的数据进行Meta分析. 结果共获得15个符合标准的研究.其中10个研究比较了吡柔比星和丝裂霉素的疗效,Meta分析显示,吡柔比星预防膀胱肿瘤复发的疗效显著优于丝裂霉素(OR=0.41,95%CI0.27～0.61,P＜0.01);6个研究分别比较了吡柔比星与噻替哌(OR=0.35,95%CI 0.11～1.13,P＞0.05)、阿霉素(OR=0.15,95%CI 0.03～0.76,P＜0.05)、表阿霉素(OR=0.53,95%CI 0.23～1.23,P＞0.05)、羟基喜树碱(OR=0.25,95%CI 0.10～0.64,P＜0.05)等药物以及空白对照组的疗效,统计学分析显示吡柔比星疗效显著优于羟基喜树碱、阿霉素以及空白对照组,而与噻替哌和表阿霉素疗效的差异无统计学意义. 结论吡柔比星能有效预防膀胱肿瘤术后复发,其疗效优于丝裂霉素、羟基喜树碱、阿霉素等药物,是新的可选择的膀胱肿瘤灌注化疗药物.

An efficacy comparison of pirarubicin with other intravesicai chemotherapeutic agents in preventing blad der tumor recurrence:a Meta-analysis

Objective To compare the efficacy of pirarubicin with other intravesical chemothera peutic agents in preventing bladder tumor recurrence. Methods Databases such as Medline,EM Base,CBMDisc and PubMed,ScienceDirect,LWW,Springer,CJFD(Chinese Journal Fulhext Data base)and Chinese Periodicals Database of Science and Technology were systematicallv searehed for controlled studies involved with intravesical pirarubicin for the treattnent of bladder cancer.Eligible studies according to inclusion and exclusion criteria were selected,then recurrence data from included studies were retrieved for a meta-analysis. Results Fifteen studies met the inclusion criteria.Of these studies 10 compared efficacy of pirarubicin with mitomycin C,and the meta-analysis based on these 10 studies showed that pirarubicin was statistically superior to mitomycin C(OR=0.41,95%CI 0.27～0.61,P＜0.01).Of 6 studies,pirarubicin was compared with thiotepa(OR=0.35,95%CI 0.11～1.13,P＞0.05),adriamyein(OR=0.15,95% CI 0.03～O.76,P＜0.05),epirubicin(OR=0.53,95% CI 0.23～1.23,P＞0.05),hydroxycamptothecin(OR=0.25,95% CI 0.10～0.64,P＜0.05)and blank control respectively,statistical analysis indicated pirarubicin was significantly better than adriamycin,hydroxycamptothecin and blank control,and not statistically different from thiotepa and epirubicin. Conclusion Pirarubicin is effective in preventing bladder tumor recurrence,with efficacy better than chemotherapeutic agents such as mitomycin C,hydroxyeamptothecin,and adriamycin,thus can be a novel optional intravescial chemotherapeutic agent for bladder cancer.